CONSTELLATION PHARMACEUTICALS INC
DelistedCIK 1434418fmd_15NP799P0BKG6Y3782YV90083JManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Mar 31, 2021, 18 periods
Latest annual · FY2018
Millions- Total revenues
- 0
- Operating income
- (125)
- Net income
- (126)
- Free cash flow
- (112)
Latest quarter · Q1 FY2021
Millions- Operating income
- (40)
- Net income
- (40)
- Free cash flow
- (40)
CONSTELLATION PHARMACEUTICALS INC financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2020 | FY2019 | Change | Source |
|---|---|---|---|---|
| Operating income | -$124.8 million | -$86.1 million | 10-K 2021-02-24 · proof | |
| Net income | -$126.4 million | -$85.6 million | 10-K 2021-02-24 · proof | |
| Cash from operating activities | -$111.4 million | -$72.2 million | 10-K 2021-02-24 · proof | |
| Free cash flow | -$112.4 million | -$72.9 million | 10-K 2021-02-24 · proof | |
| Total assets | $441.9 million | $399.1 million | +10.7% | 10-K 2021-02-24 · proof |
| Total liabilities | $31.1 million | $61.5 million | -49.4% | 10-K 2021-02-24 · proof |
| Cash and cash equivalents | $163.7 million | $334.3 million | -51% | 10-K 2021-02-24 · proof |
- What was CONSTELLATION PHARMACEUTICALS INC's operating income in fiscal 2020?
- CONSTELLATION PHARMACEUTICALS INC reported operating income of -$124.8 million for fiscal 2020 (the year ended Dec 31, 2020), against -$86.1 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2021. SEC
- What was CONSTELLATION PHARMACEUTICALS INC's net income in fiscal 2020?
- CONSTELLATION PHARMACEUTICALS INC reported net income of -$126.4 million for fiscal 2020 (the year ended Dec 31, 2020), against -$85.6 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2021. SEC
- What was CONSTELLATION PHARMACEUTICALS INC's cash from operating activities in fiscal 2020?
- CONSTELLATION PHARMACEUTICALS INC reported cash from operating activities of -$111.4 million for fiscal 2020 (the year ended Dec 31, 2020), against -$72.2 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2021. SEC
- What was CONSTELLATION PHARMACEUTICALS INC's free cash flow in fiscal 2020?
- CONSTELLATION PHARMACEUTICALS INC reported free cash flow of -$112.4 million for fiscal 2020 (the year ended Dec 31, 2020), against -$72.9 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2021. SEC
- What are CONSTELLATION PHARMACEUTICALS INC's total assets?
- As of Dec 31, 2020, CONSTELLATION PHARMACEUTICALS INC reported total assets of $441.9 million, against $399.1 million a year earlier (+10.7%). Source: the 10-K filed with the SEC on Feb 24, 2021. SEC
- What are CONSTELLATION PHARMACEUTICALS INC's total liabilities?
- As of Dec 31, 2020, CONSTELLATION PHARMACEUTICALS INC reported total liabilities of $31.1 million, against $61.5 million a year earlier (-49.4%). Source: the 10-K filed with the SEC on Feb 24, 2021. SEC
- What are CONSTELLATION PHARMACEUTICALS INC's cash and cash equivalents?
- As of Dec 31, 2020, CONSTELLATION PHARMACEUTICALS INC reported cash and cash equivalents of $163.7 million, against $334.3 million a year earlier (-51%). Source: the 10-K filed with the SEC on Feb 24, 2021. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1434418&period_type=annual&limit=5"Information only, not investment advice.